Oppenheimer analyst Leland Gershell downgraded Milestone Pharmaceuticals (NASDAQ: MIST) from Outperform to Perform.The analyst commented, "Primary endpoint miss in intranasal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE